miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer

BACKGROUND: Ovarian cancer is the leading lethal gynecological cancer and is generally diagnosed during late-stage presentation. In addition, patients with ovarian cancer still face a low 5-year survival rate. Thus, innovative molecular targeting agents are required to overcome this disease. The pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Shujun, Li, Na, Liao, Xihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851903/
https://www.ncbi.nlm.nih.gov/pubmed/33526047
http://dx.doi.org/10.1186/s13048-020-00760-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851903/
https://www.ncbi.nlm.nih.gov/pubmed/33526047
http://dx.doi.org/10.1186/s13048-020-00760-2

Ejemplares similares